Schizophrenia

Monday 16th May 2022, Time: 14:00 (CEST)

Schizophrenia and related psychiatric disorders can be highly disabling. New research demonstrates the evidence for cognitive enhancement therapies, capable of relieving these deficits. This webinar will review the evidence for cognitive enhancement therapies and their mode of action, making recommendations for individualized implementation strategies. The topics covered will include computer-based exercises, psychotherapeutic group activities, and pharmacological interventions, as well as efforts to implement cognitive enhancement approaches in community settings

Prof Afzal Javed President World Psychiatric Association

Prof Peter Morozov Secretary General World Psychiatric Association

Schizophrenia Clinical Trials - what they tell us?

Friday 27th May 2022, Time: 14:00 (CEST)

Clinical trials are the cornerstone of current evidence-based medicine. Designs range from effectiveness trials with maximized internal validity but limited external generalizability, to effectiveness and large simple trials that maximize external validity but have reduced precision. Data analytics have equally evolved and become very sophisticated, and it has become increasingly important to choose the most appropriate statistical analysis plan for a given trial design, research question and attempt at minimising type I and/or type II error. Trial design, conduct and interpretation are critical components that need to be focused on. Both failed and successful trials provide an opportunity for learning.

Prof Afzal Javed President World Psychiatric Association

Prof Peter Morozov Secretary General World Psychiatric Association

Individualised Management of Schizophrenia

Friday 7th July 2022, Time: 17:00 (CEST)

Negative symptoms are present in more than 50% of people with schizophrenia, have a significant impact on real-life functioning, and pose a substantial burden on the affected people and their families. This webinar will focus on: 1) psychopathological constructs currently regarded as relevant to the negative symptom dimension; 2) the distinction between primary and secondary negative symptoms and its relevance to clinical practice; 3) the main differences among current definitions of deficit schizophrenia, persistent negative symptoms, prominent negative symptoms and predominant negative symptoms; 4) recommendations for recognizing and assessing negative symptom domains with the appropriate tools.

Prof Afzal Javed, President WPA

Prof Peter Morozov, Secretary General WPA

Prof. Roger Ng, Secretary Education, WPA

Schizophrenia - Before Assuming Non-Response to Antipsychotic Treatment

Friday 14th July 2022, Time: 14:00 (CEST)

Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Symptoms typically come on gradually, begin in young adulthood, and in many cases never resolve. About half of those diagnosed with schizophrenia will have a significant improvement over the long term with no further relapses, and a small proportion of these will recover completely. The other half will have a lifelong impairment. In some cases, people may be repeatedly admitted to hospitals. Social problems such as long-term unemployment, poverty, homelessness, exploitation, and victimization are commonly correlated with schizophrenia. The mainstay of treatment is antipsychotic medication, along with counselling and social rehabilitation.

Prof Afzal Javed, President WPA

Prof Peter Morozov, Secretary General WPA

Prof. Roger Ng, Secretary Education, WPA